大学院医学研究院

研究キーワード

慢性肝疾患 ,肝細胞癌

研究分野

ライフサイエンス / 腫瘍診断、治療学 / 肝細胞癌

学歴

2016年4月

-

2020年3月

千葉大学大学院医学研究院医学薬学府博士課程

論文

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.

Sadahisa Ogasawara Keisuke Koroki Hirokazu Makishima Masaru Wakatsuki Asahi Takahashi Sae Yumita Miyuki Nakagawa Takamasa Ishino Keita Ogawa Kisako Fujiwara Terunao Iwanaga Takafumi Sakuma Naoto Fujita Ryuta Kojima Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Yoshihito Ozawa Yohei Kawasaki Tomoya Kurokawa Hideki Hanaoka Hiroshi Tsuji Naoya Kato

BMJ open 12(4) e059779 2022年4月

INTRODUCTION: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus pa...

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Keisuke Koroki Naoya Kanogawa Susumu Maruta Sadahisa Ogasawara Yotaro Iino Masamichi Obu Tomomi Okubo Norio Itokawa Takahiro Maeda Masanori Inoue Yuki Haga Atsuyoshi Seki Shinichiro Okabe Yoshihiro Koma Ryosaku Azemoto Masanori Atsukawa Ei Itobayashi Kenji Ito Nobuyuki Sugiura Hideaki Mizumoto Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Tomoko Saito Takayuki Kondo Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Naoya Kato

Liver cancer 10(5) 473-484 2021年9月

BACKGROUND: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore can...

Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Ryoi Yoshida Keisuke Koroki Hirokazu Makishima Sadahisa Ogasawara Takamasa Ishino Keita Ogawa Miyuki Nakagawa Kisako Fujiwara Hidemi Unozawa Terunao Iwanaga Naoto Fujita Takafumi Sakuma Hiroaki Kanzaki Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Takashi Kaneko Masaru Wakatsuki Jun Kato Hiroshi Tsuji Naoya Kato

CASE REPORTS IN ONCOLOGY 14(2) 1103-1110 2021年

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemi...

Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.

Keisuke Koroki Sadahisa Ogasawara Yoshihiko Ooka Hiroaki Kanzaki Kengo Kanayama Susumu Maruta Takahiro Maeda Masayuki Yokoyama Toru Wakamatsu Masanori Inoue Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Eiichiro Suzuki Shingo Nakamoto Shin Yasui Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Satoshi Kuboki Masayuki Ohtsuka Masaru Miyazaki Osamu Yokosuka Naoya Kato

Liver cancer 9(5) 596-612 2020年9月

Background: Intermediate-stage hepatocellular carcinoma (HCC) has a high frequency of recurrence and progression to advanced stage after transarterial chemoembolization (TACE), particularly in patients with high tumor burden. Promising new results...

もっとみる